Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415499 | 1.00 | CYP11B1 (0.32) | CYP11B1CYP11B2LMNAALDH1A1TSHR | |
| SCHEMBL23298053 | 1.00 | CYP11B1 (0.32) | CYP11B1CYP11B2LMNAALDH1A1TSHR | |
| SCHEMBL28833909 | 0.81 | KCNA3 (0.34) | LMNAALDH1A1TSHRCHRM2CHRM1 | |
| SCHEMBL20595723 | 0.81 | KCNA3 (0.34) | LMNAALDH1A1TSHRCHRM2CHRM1 | |
| SCHEMBL20595800 | 0.81 | KCNA3 (0.34) | LMNAALDH1A1TSHRCHRM2CHRM1 | |
| SCHEMBL4290185 | 0.80 | TEAD1 (0.35) | LMNAALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL15412695 | 0.79 | ATM (0.36) | LMNA | |
| SCHEMBL15412932 | 0.79 | ATM (0.36) | LMNA | |
| SCHEMBL15412693 | 0.79 | ATM (0.36) | LMNA | |
| SCHEMBL17923226 | 0.78 | CHRM2 (0.38) | LMNATSHRCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-08 | — | — | US | disclosed |
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4054720-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | disclosed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | CYP11B1 2179/4885CYP11B2 2567/4885LMNA 3756/4885 |
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP11B1 4095/4885CYP11B2 4359/4885LMNA 3803/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | CYP11B1 4102/4885CYP11B2 4486/4885LMNA 4799/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CYP11B1 3005/4885CYP11B2 3512/4885LMNA 3858/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | CYP11B1 1240/4885CYP11B2 1552/4885LMNA 3276/4885 |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DPP4, DPP7, DPP3 | CYP11B1 1223/4885CYP11B2 1803/4885LMNA 3331/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP11B1 4095/4885CYP11B2 4359/4885LMNA 3803/4885 |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | CYP11B1 4198/4885CYP11B2 4407/4885LMNA 4373/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP11B1 3907/4885CYP11B2 4204/4885LMNA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.